Cargando…
Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats
Botulinum neurotoxins (BoNT) are potential biothreat agents due to their high lethality, potency, and ease of distribution, thus the development of antitoxins is a high priority to the US government. This study examined pre-clinical pharmacokinetic studies in rats of four oligoclonal anti-BoNT mAb-b...
Autores principales: | Espinoza, Yero, Wong, David, Ahene, Ago, Der, Kenneth, Martinez, Zachary, Pham, John, Cobb, Ronald R., Farr-Jones, Shauna, Marks, James. D., Tomic, Milan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628388/ https://www.ncbi.nlm.nih.gov/pubmed/31212950 http://dx.doi.org/10.3390/toxins11060345 |
Ejemplares similares
-
Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model
por: Tomic, Milan T., et al.
Publicado: (2021) -
Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination against Botulinum C and D Neurotoxins
por: Snow, Doris M., et al.
Publicado: (2019) -
Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model
por: Tomic, Milan T., et al.
Publicado: (2019) -
A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model
por: Snow, Doris M., et al.
Publicado: (2021) -
Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials
por: Xiang, Hong, et al.
Publicado: (2021)